Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. It is not yet known whether erlotinib is more effective than a
placebo in treating non-small cell lung cancer.
PURPOSE: This randomized phase III trial is studying erlotinib to see how well it works
compared to a placebo in treating patients with stage III or stage IV non-small cell lung
cancer.